论文部分内容阅读
目的观察替吉奥单药化疗联合调强放射治疗老年中晚期食管癌的疗效和安全性。方法收集本科2011年1月-2012年9月收治的27例不能手术的70岁以上老年中晚食管癌患者,替吉奥单药化疗联合调强放射治疗;放射治疗采用调强放射治疗技术,每周5次,每次DT1.8Gy,总放疗剂量为DT59.4Gy,在放疗第ld开始口服替吉奥胶囊40mg,2次/d,14d为1个疗程,休息1周后继续口服第2个疗程。放疗结束后4周复查食管造影及CT。结果入组27例患者均完成放化疗,完全缓解率51.9%(14/27)、有效率92.6%(25/27)。毒副作用主要为放射性食管炎、骨髓抑制、胃肠道反应等。结论吉奥单药化疗联合调强放射治疗老年中晚期食管癌有较好的近期疗效,且替吉奥口服方便,不良反应较轻,其远期疗效及不良反应有待进一步观察研究。
Objective To observe the efficacy and safety of ticrogir monotherapy combined with intensity-modulated radiation in the treatment of advanced esophageal cancer in elderly patients. Methods A total of 27 inoperable patients with middle or advanced esophageal cancer over the age of 70 were enrolled in our department from January 2011 to September 2012. The patients were treated with single-agent chemotherapy combined with intensity-modulated radiation therapy. Radiotherapy was performed with intensity- 5 times a week, each DT1.8Gy, the total radiation dose of DT59.4Gy, in the first day of radiotherapy oral tigegio capsule 40mg, 2 times / d, 14d for a course of treatment, rest for 1 week after oral 2 A course of treatment. Four weeks after radiotherapy, esophagectomy and CT were reviewed. Results All the 27 patients completed the chemoradiotherapy. The complete remission rate was 51.9% (14/27), the effective rate was 92.6% (25/27). The main side effects of radiation esophagitis, bone marrow suppression, gastrointestinal reactions. Conclusion Gio single-agent chemotherapy combined with intensity-modulated radiation therapy has a good short-term curative effect on advanced esophageal cancer in elderly patients. It is convenient for oral administration and has mild side effects. Its long-term curative effect and side effects need further study.